Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: A personal viewpoint

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 4, 2002, Pages 335-340

  Rawson, Nigel S B ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; NEW DRUG;

ARTICLE; CANADA; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FINANCIAL MANAGEMENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESPONSIBILITY; UNITED STATES; HEALTH PERSONNEL ATTITUDE; METHODOLOGY; REVIEW; STATISTICS;

ATTITUDE OF HEALTH PERSONNEL; CANADA; DRUG APPROVAL; PRODUCT SURVEILLANCE, POSTMARKETING; SUPPORT, NON-U.S. GOV'T;

EID: 0036307005     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.740     Document Type: Article

References (56)

1. Pharmacoepidemiology in Thailand: A personal opinion
2. Pharmacoepidemiology in developing countries: What can ISPE do?
3. Current status of drug safety monitoring in Korea
4. Cisapride, before and after: Still waiting for ADE-reporting reform
5. Report of the Commission of Inquiry on the Pharmaceutical Industry
6. Health and Sports Program: A Study Team Report to the Task Force on Program Review
7. Report to the House of Commons, Fiscal Year Ending 31 March 1987
8. Memorandum to the Minister (the Stein Report)
9. Program Evaluation Study of the Drug Safety, Quality and Efficacy Program
10. Working in Partnerships...Drug Review for the Future
11. Drug review in Canada: A comparison with Australia, Sweden, the United Kingdom, and the United States
12. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998
13. AIDS activists condemn slow drug-approval process
14. First to start, last to finish: Approvals track record is poor
15. Loosening the cap on drug approvals
16. Prescription for Performance: A National Summit
17. Drug-approval process too slow, activists argue
18. Waiting for approval: Canada's hidden drug problem
19. Speed up drug-approval process, feds told
20. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998
21. Therapeutic Products Program: Baseline Assessment of Drug Submission Review Process
22. Drug Submission Evaluation: International Comparison of Performance Standards and Performance
23. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States
24. A dog's breakfast: Prescription drug coverage varies widely across Canada
25. Access to new medicines
26. Evaluation of Provincial Procedures for Drug Listing, Specifically Focussed on Approaches to Cost-effectiveness
27. Postmarketing surveillance in Canada
28. Adverse drug reaction reporting II: Evaluation of the Saskatchewan pilot project for a regional reporting program in Canada
29. Effectiveness of a Regional Reporting Program in Improving Quality of Adverse Drug Reaction Case Reports
30. Health databases in Saskatchewan
31. Incidence of lactic acidosis in metformin users
32. Incidence of adverse oesophageal and gastric events in alendronate users
33. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting
34. Postmarketing surveillance of medications and pregnancy outcomes: Clarithromycin and birth malformations
35. Tramadol and seizures: A surveillance study in a managed care population
36. Canada needs better drug reporting, says inquest
37. Health Canada, drug firm face $100m lawsuit
38. Action plan to address inquest recommendations for Health Canada
39. Lotronex and the FDA: A fatal erosion of integrity
40. New challenges in quality control and licensure: Regulation
41. 'Effectiveness' in the evaluation of new drugs: A misunderstood concept?
42. An acute adverse drug reaction alerting scheme using the Saskatchewan Health datafiles
43. Impact of pre-existing health conditions on the outcome of an adverse drug reaction alerting scheme: Gastrointestinal disorders before piroxicam and sulindac therapy
44. An acute adverse event signalling scheme using the Saskatchewan administrative health care utilization datafiles: Results for two benzodiazepines
45. Experience in the development of a postmarketing surveillance network: The Pharmacy Medication Monitoring Program
46. A methodologic study of post-marketing drug evaluation using a pharmacy-based approach
47. Prescription-Event Monitoring: Methodology and recent progress
48. The New Zealand Intensive Medicines Monitoring Programme
49. Patient self-monitoring: A challenging approach to pharmacoepidemiology
50. Could 'conditional release' of new drugs provide the information required to study drug effectiveness? - A discussion paper
51. The future of health care in Canada
52. Canadian Medicare needs choice